Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 13,466 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Type 1 Diabetes Mellitus
Interventions: cyclosporin and methotrexate; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 8 Years to 18 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1990 – 1994
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Acromegaly
Interventions: Pegvisomant, Octreotide LAR, Lanreotide; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome
Interventions: Telemedicine, Face-to-Face; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Henderson, North Carolina • Laurinburg, North Carolina • Lumberton, North Carolina + 1 more

Conditions: Healthy
Interventions: LowT, Resistance Training, Placebo, HighT; Drug · Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 60 Years and older · Male only
Enrollment: 167 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Type 2 Diabetes
Interventions: chromium picolinate 1000 mcg daily vs placebo, Placebo; Dietary Supplement · Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 25 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: biphasic insulin aspart 30; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 15
States / cities: Phoenix, Arizona • La Jolla, California • DeLand, Florida + 11 more

Conditions: Prostate Cancer
Interventions: flutamide, Zoladex, Lupron, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 2,028 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2018
U.S. locations: 222
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 173 more

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: insulin degludec, insulin glargine, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 92
States / cities: Birmingham, Alabama • Goodyear, Arizona • Concord, California + 81 more

Conditions: Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Pemigatinib, Computed Tomography (CT), Magnetic Resonance Imaging, Optical Coherence Tomography, Bone Scan, Ophthalmoscopy; Drug · Procedure
Lead sponsor: Sameek Roychowdhury; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 109
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 106 more

Conditions: Pancreatic Neoplasms
Interventions: EUS with Fiducial; Device
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypogonadism
Interventions: Testosterone MD-Lotion; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 11
States / cities: Birmingham, Alabama • Tuscon, Arizona • Burbank, California + 8 more

Conditions: Diabetic Retinopathy
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pressure Ulcer, Foot Ulcer, Diabetic
Interventions: Santyl, Standard Care; Biological · Other
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pancreatic Cancer
Interventions: fluorouracil, rubitecan; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: San Ramon, California

Conditions: Heart Failure, Type 2 Diabetes, Chronic Kidney Diseases
Interventions: Virtual Consult Intervention; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Vitamin D Deficiency, Metabolic Syndrome, Prediabetes
Interventions: Mushroom with 600 IU vitamin D2, Mushroom with 4000 IU Vitamin D2, 600 IU Vitamin D3 and untreated mushroom, 4000 IU Vitamin D3 and untreated mushroom, Placebo; Dietary Supplement · Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 30 Years to 90 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Thyroid
Interventions: Pembrolizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pancreatic Ductal Adenocarcinoma (PDAC), Family History of Pancreas Cancer, Genetic Testing, Multi-cancer Early Detection
Interventions: Telephone education session, Online educational materials; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes, Obesity, Pediatric Obesity
Interventions: Lifestyle Intervention; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 10 Years to 99 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Type 2 Diabetes Mellitus, Walking
Interventions: Not listed
Lead sponsor: University of Massachusetts, Amherst; Other
Eligibility: 40 Years to 65 Years
Enrollment: 20 participants
Timeline: 2019
U.S. locations: 1
States / cities: Amherst, Massachusetts

Conditions: Diabetes, Diabetes Mellitus
Interventions: The Biolinq MicroArray Intradermal Continuous Glucose Biowearable System; Device
Lead sponsor: Biolinq Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Idaho Falls, Idaho

Conditions: Diabetes, Type 1 Diabetes
Interventions: Daily feedback, Financial incentive; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 14 Years to 20 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pancreatic Cancer
Interventions: fluorouracil, gemcitabine hydrochloride, brachytherapy, phosphorus P32, radiation therapy; Drug · Radiation
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Foot Ulcer, Diabetes
Interventions: KC-002, Conventional Wound Therapy; Device · Other
Lead sponsor: KeraCure; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 21
States / cities: Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more

Search by objective public record fields.

Low Dose Cyclosporin and Methotrexate Therapy in Diabetes

Acromegaly Combination Treatment Study

Telemedicine vs. Face-to-Face Cancer Genetic Counseling

TEAM: Testosterone Supplementation and Exercise in Elderly Men

Effect of Chromium Picolinate on Insulin Sensitivity in Type 2 Diabetes

Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

EUS Fiducial for Pancreas Surgery

A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations

Long-Term Follow-Up of Patients Enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS)

Use of Santyl Within an Accountable Care Organization

Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer

Optimizing In-hospital Use of Evidence-based Therapies for Patients With Cardio-Renal-Metabolic Disease

Bioavailability and Biological Effects of Vitamin D2 Contained in Mushroom

IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC

Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial

Preventing Diabetes in Latino Families

Cadence and Intensity in Adults With Type 2 Diabetes

Biolinq External Interferent Protocol

Behavioral Economic Incentives to Improve Glycemic Control Among Adolescents and Young Adults

Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regionally Advanced Unresectable Adenocarcinoma of the Pancreas

Safety and Efficacy Study of an Interactive Wound Dressing (KC002) for the Treatment of Diabetic Foot Ulcers